Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal
Selma Ugurel

Showing results (401-410 of 411) with videos related to

Pageof 42
Sort By:
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Nature Communications|March 2, 2018
Single cell polarity in liquid phase facilitates tumour metastasisAnna Lorentzen, Paul F Becker, Jan Kosla, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2025
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence studyMichael Weichenthal, Eva Ellebaek, Joanna Mangana, et al.
Nature|July 6, 2017
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerUgur Sahin, Evelyna Derhovanessian, Matthias Miller, et al.
Pageof 42

Showing results (401-410 of 411) with videos related to

Sort By:
Pageof 42
Nature Medicine|December 4, 2019
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaDavid Liu, Bastian Schilling, Derek Liu, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Nature Communications|March 2, 2018
Single cell polarity in liquid phase facilitates tumour metastasisAnna Lorentzen, Paul F Becker, Jan Kosla, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2021
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionSarah Knispel, Maximilian Gassenmaier, Alexander M Menzies, et al.
Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2025
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence studyMichael Weichenthal, Eva Ellebaek, Joanna Mangana, et al.
Nature|July 6, 2017
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancerUgur Sahin, Evelyna Derhovanessian, Matthias Miller, et al.
Pageof 42